Özet:

Purpose: To investigate the effects of intra-vitreal ranibizumab (IVR) monotherapy and IVR+intra-vitreal triamsinolone (IVTA) combination therapy on visual severity (GK) and central foveal thickness (SFK) in the treatment of diabetic macular ointment (DMO). Tools and Methods: 52 eyes of 37 patients with clinically meaningful DMO were included in the study. All patients were initially administered 0.5 mg / 0.05 ml of ranibizumab intra-vitreal pathway. In cases where 2 ranibizumab injections did not receive adequate response, IVR+IVTA combination therapy was applied. Vision accuracy and SFK values were compared before and 1, 3 and 6 months after the injection. Results: The average vision accuracy before injection is 0.68 ± 0.42 logMAR. In the first and third months, a statistically significant increase in vision accuracy was observed compared to pre-injection values (p<0.05). Although vision sharpness increased in the sixth month, the difference between the groups was not statistically meaningful (p>0.05). Before the injection, the average SFK value was 557.4±157.7 μm. A statistically significant decrease in SFK values in 1, 3 and 6 months compared to pre-injection SFK was observed (p<0.05). Patients with IVR and IVR+IVTA combination treatment compared to 6 month results, the average GK was 0.60±0.41 logMar and 0.58±0.38 logMar respectively; the average SFK values were 419.35±205.5 μm and 487.0±215.5 μm respectively. There was no statistically significant difference between the two groups (p>0.05). The result: IVR+IVTA combination therapy may be an alternative method in resistant DMO phenomena along with intra-vitreal ranibizumab monotherapy.

Anahtar Kelimeler: